Between Breakthroughs and Reality: Erik Halvorsen on What It Takes to Bring Science to Market
Drug discovery has never suffered from a lack of ideas. What it has struggled with is translation: turning promising science into real therapies that can withstand biological complexity, development risk, and market pressure. Even as new computational tools flood the field, the gap between what looks compelling and what actually scales remains stubbornly wide.
Erik Halvorsen has spent more than two decades operating precisely in that gap.
As a scientist trained in neuropharmacology, an entrepreneur who has built and backed companies across therapeutics, genomics, robotics, and digital health, as well as a partner at pH Partners advising life sciences companies on financing, partnerships, and strategy, Erik has seen first-hand why so many approaches falter and why only a few succeed. His career has been shaped not by hype cycles, but by pattern recognition: understanding what endures once early excitement gives way to execution.
That perspective matters now more than ever. The drug discovery landscape is increasingly crowded with AI-driven promises, yet the hardest problems—novel targets, complex diseases, reproducibility, and real-world validation—remain unsolved. As a long-time advisor to the company, Erik understands that FAR Biotech’s work sits squarely inside this tension, tackling hard-to-drug diseases with a fundamentally different computational approach. But this isn’t about a single company or technology. It’s about the deeper question underneath them all: what does it actually take to bring transformative science into the world?
In this interview, Erik shares how he evaluates emerging discovery platforms, what today’s biotech market is rewarding (and rejecting), where he sees genuine opportunity for patient impact, and why discipline, realism, and scientific grounding matter just as much as innovation. For anyone interested in the future of drug discovery or how breakthrough science becomes durable value, his perspective offers a rare, clear-eyed view.
Across therapeutics, diagnostics, robotics, genomics, and digital health, when you look back over 20 years in life sciences, what through-lines do you see in technologies that successfully move from the lab to commercial reality?
Erik Halvorsen: When I step back and look across all of those categories, two of the biggest through-lines I see are reproducibility and timely execution. A lot of really interesting science comes out of academic environments, but when you try to move it forward, you realize how difficult it can be to reproduce results and then translate to commercial success consistently.
The companies that ultimately succeed are the ones that can achieve independent validation and “proof of concept” as quickly and cash efficiently as possible. They invest the time to really understand their innovation in the context of what already exists, stress‑test their assumptions, and build processes around validating what they’re seeing. Maintaining focus leads to timely execution hitting key milestones, derisking the technology, and creating value. The technologies that make it through tend to be very clear about the specific problem they’re solving and who they’re solving it for. They resist the urge to chase too many opportunities at once and instead align the science, the clinical need, and a realistic path to market.
As both a scientist and an investor, what signals help you distinguish between a compelling scientific idea and a platform that can realistically scale?
Erik Halvorsen: For me, one of the biggest signals is whether the team understands the constraints as well as the opportunities. A compelling scientific idea is exciting, but a scalable platform requires discipline. I pay a lot of attention to whether a team can talk clearly about the challenges, priorities, timelines, and tradeoffs, not just upside.
Another signal is repeatability. If a platform can generate one interesting result, that’s encouraging. But if it can generate consistent outcomes across multiple programs or applications, that’s usually a sign that it can scale. I also look at how the team thinks about integration: How the technology fits into existing development workflows and how it will actually be used in practice.
You’ve founded companies, launched early-stage funds, and helped build major innovation ecosystems. What do you think the industry still misunderstands about how breakthrough biotech companies are actually built?
Erik Halvorsen: I think there’s still a misconception that breakthrough biotech happens quickly or in a straight line. In reality, it’s almost always iterative. There are setbacks, unexpected results, and periods where progress feels slower than anyone would like. The companies that make it are usually the ones that have leadership and investors who can tolerate that uncertainty without constantly changing direction.
There’s also sometimes too much emphasis on the initial idea and not enough on execution. A strong idea is important, but execution—how decisions are made, how teams work together, how tradeoffs are handled under pressure—often ends up being the difference between success and failure.
Your training is in neuropharmacology. How has that scientific foundation shaped the way you evaluate emerging drug discovery approaches today?
Erik Halvorsen: Having that background means that for therapeutics, I naturally spend a lot of time thinking about mechanisms of action and clinical relevance. I’m always asking whether an approach really maps onto what we understand about disease biology and whether it has a reasonable chance of translating into something meaningful for patients.
It also makes me cautious about oversimplification. Biology is complex, and while new computational and experimental tools are incredibly powerful, they still have to engage with that complexity rather than trying to abstract it away entirely.
From your perspective, what capabilities or philosophies need to be in place for computational drug discovery methods to translate into clinically and commercially meaningful molecules?
Erik Halvorsen: I think it starts with respect for the underlying science. Computational approaches work best when they’re grounded in a deep understanding of physics, chemistry, biology, and physiology, rather than being treated as a black box that magically produces answers.
It’s also critical that these methods are tightly integrated with experimental validation. Most drug development teams will see computation and experimentation as complementary. Powerful drug discovery and drug translation platforms can help narrow the search space and and accelerate the process and reduce the cost to deliver potential “hits” for drug development, but ultimately experimental validation is still required to test, refine and select the most promising “leads” that will progress into clinical development and hopefully make their way to patients.
Wearing your pH Partners hat for a moment, how would you describe the current biotech market? What dynamics are shaping how capital is being deployed today?
Erik Halvorsen: The market today is definitely more selective than it was a few years ago for pre-clinical or pre-market stage companies. Capital is still available, but investors have a high bar and diligence processes are more exhaustive. There’s always been a focus on the science and the team, but investors want innovations that are transformational not incremental. Companies need to have clear value propositions, credible development plans, and realistic paths to partnership or exit.
At the same time, I think this environment actually rewards teams that are thoughtful and disciplined. Companies that can show steady, tangible progress, hitting their milestones on time and on budget, tend to stand out more clearly and are rewarded with more investor confidence and follow-on funding.
In this market environment, what types of biotech companies or platforms are best positioned to attract partnership or investment interest?
Erik Halvorsen: Platforms that address real unmet needs and demonstrate a clear point of differentiation are generally best positioned. Investors and partners want to see evidence that a company can do something others can’t, and that this difference matters clinically or commercially.
There’s also a lot of interest in platforms that create multiple shots on goal which leads to optionality in development and partnering. Companies that can pursue multiple programs or applications tend to be more resilient and more attractive than those tied to a single asset or binary outcome.
You’ve advised many founders through pivotal moments like financings, partnerships, and strategic pivots. What tend to be the most consequential inflection points in a young biotech company’s journey?
Erik Halvorsen: Early strategic decisions often have a much bigger impact than people realize at the time. Choices about which programs to prioritize, when to seek partnerships, and how to allocate limited resources can shape the company’s trajectory for years. For any company, but especially early stage companies, assembling a strong Board of Directors with people who have “been there and done that” is critical to success and navigating through those key strategic decisions.
Another major inflection point is how a team responds to unexpected data, whether it’s positive or negative. Those moments tend to reveal a lot about leadership, culture, and the ability to adapt without losing focus.
Having served on multiple boards, what qualities do you look for in scientific and executive leadership when evaluating whether a team can execute under pressure?
Erik Halvorsen: The CEO must be seen as a domain expert and be an effective communicator whether with scientists, clinicians, investors or their team. Good leaders need to have clarity of vision but with the humility to listen to others and the resilience required to navigate the bumpy road ahead.
Trust within the team is also critical. When people trust one another, they’re able to make difficult decisions more quickly and with greater confidence, especially in high-pressure situations.
Looking ahead five to ten years, where do you feel most optimistic about progress in drug discovery, and what unresolved challenges still concern you?
Erik Halvorsen: I’m optimistic about the continued integration of new tools and methodologies in drug development that allow us to tackle problems that were previously considered intractable. There’s real momentum building in several areas across the entire drug development continuum that have struggled for decades.
At the same time, the fundamental challenges such as biology, clinical development cost, and timelines haven’t appreciably changed. Balancing innovation with those realities will remain one of the central challenges for the field moving forward.
Bringing transformative science into the world is rarely about a single breakthrough. It’s about judgment, discipline, and the ability to navigate uncertainty over time. Erik Halvorsen’s career reflects that reality, shaped by years spent evaluating what endures once early promise meets biological, operational, and market constraints. As drug discovery enters a new era of computational possibility, his perspective serves as a reminder that progress is built not just on new tools, but on clear thinking, scientific rigor, and teams willing to do the hard work required to translate insight into impact.
